JP2011515478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515478A5 JP2011515478A5 JP2011501946A JP2011501946A JP2011515478A5 JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5 JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- antibody
- cdr
- ser
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3919708P | 2008-03-25 | 2008-03-25 | |
| US61/039,197 | 2008-03-25 | ||
| PCT/US2009/037953 WO2009142810A2 (en) | 2008-03-25 | 2009-03-23 | Methods for treating or preventing colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515478A JP2011515478A (ja) | 2011-05-19 |
| JP2011515478A5 true JP2011515478A5 (https=) | 2013-03-14 |
Family
ID=41340744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501946A Pending JP2011515478A (ja) | 2008-03-25 | 2009-03-23 | 結腸直腸がんを処置または予防するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110104256A1 (https=) |
| EP (1) | EP2259797A2 (https=) |
| JP (1) | JP2011515478A (https=) |
| CA (1) | CA2718918A1 (https=) |
| CL (1) | CL2009000721A1 (https=) |
| MX (1) | MX2010010480A (https=) |
| TW (1) | TW200944233A (https=) |
| WO (1) | WO2009142810A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| BRPI0914790A2 (pt) | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| ES2645692T3 (es) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| TWI460178B (zh) | 2009-02-12 | 2014-11-11 | Arqule Inc | 組合性組成物及治療癌症之方法 |
| DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US8580764B2 (en) * | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| EP2611443A2 (en) | 2010-09-01 | 2013-07-10 | ArQule, Inc. | Methods for treatment of non-small cell lung cancer |
| WO2013162368A1 (en) * | 2012-04-26 | 2013-10-31 | Stichting Vu-Vumc | Biomarkers |
| NL2010276C2 (en) * | 2013-02-08 | 2014-08-11 | Stichting Vu Vumc | Biomarkers. |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| JP6210640B2 (ja) * | 2014-06-19 | 2017-10-11 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
| CN106999734B (zh) * | 2014-09-29 | 2020-06-16 | 得克萨斯大学体系董事会 | 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法 |
| WO2016164815A1 (en) | 2015-04-10 | 2016-10-13 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| WO2017136671A1 (en) * | 2016-02-04 | 2017-08-10 | Chattterjee Bandana | Combination therapy for castration-resistant prostate cancer |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| JP2017210493A (ja) * | 2017-09-08 | 2017-11-30 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
| JP7493237B2 (ja) * | 2018-11-14 | 2024-05-31 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| JP2021036003A (ja) * | 2020-12-05 | 2021-03-04 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
| KR20240041917A (ko) * | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00502B (me) * | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| EP1506286B1 (en) * | 2002-05-24 | 2014-03-19 | Merck Sharp & Dohme Corp. | Neutralizing human anti-igfr antibody |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| DE602004029581D1 (de) * | 2003-08-13 | 2010-11-25 | Pfizer Prod Inc | Modifizierte humane igf-1r antikörper |
| TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| JP4875064B2 (ja) * | 2005-04-15 | 2012-02-15 | シェーリング コーポレイション | 癌を処置または予防するための方法および組成物 |
| NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
| JP2009520028A (ja) * | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｉｇｆｒ抑制剤および抗癌剤の併用 |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2008005469A2 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| EP2121018A2 (en) * | 2006-12-13 | 2009-11-25 | Schering Corporation | Treating cancer with anti-igf1r antibody 19d12=sch 717454 |
| US20110129456A1 (en) * | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
-
2009
- 2009-03-23 US US12/934,458 patent/US20110104256A1/en not_active Abandoned
- 2009-03-23 EP EP09751040A patent/EP2259797A2/en not_active Withdrawn
- 2009-03-23 WO PCT/US2009/037953 patent/WO2009142810A2/en not_active Ceased
- 2009-03-23 JP JP2011501946A patent/JP2011515478A/ja active Pending
- 2009-03-23 CA CA2718918A patent/CA2718918A1/en not_active Abandoned
- 2009-03-23 MX MX2010010480A patent/MX2010010480A/es not_active Application Discontinuation
- 2009-03-24 CL CL2009000721A patent/CL2009000721A1/es unknown
- 2009-03-24 TW TW098109578A patent/TW200944233A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515478A5 (https=) | ||
| JP2011519868A5 (https=) | ||
| JP2019503674A5 (https=) | ||
| WO2008076278A4 (en) | Methods of cancer treatment with igf1r inhibitors | |
| RU2010120674A (ru) | Полностью человеческие анти-vegf-антитела и способы их применения | |
| JP2012247438A5 (https=) | ||
| RU2018123481A (ru) | Анти-lag3 антитела и антигенсвязывающие фрагменты | |
| WO2010124009A2 (en) | Fully human anti-vegf antibodies and methods of using | |
| JP2014516964A5 (https=) | ||
| AU2016355569B2 (en) | CTLA4 binders | |
| US10544222B2 (en) | PD1/CTLA4 binders | |
| US10323090B2 (en) | PD1 and/or LAG3 binders | |
| WO2019199621A4 (en) | Bi-functional molecules to degrade circulating proteins | |
| IL319363A (en) | Cervalon ligands and bifunctional compounds containing them | |
| JP2022549169A5 (https=) | ||
| EP2282739A2 (en) | Sequential administration of chemotherapeutic agents for treatment of cancer | |
| JP2011515478A (ja) | 結腸直腸がんを処置または予防するための方法 | |
| JP2005527222A5 (ja) | 中和ヒト抗ｉｇｆｒ抗体 | |
| JP2014516964A (ja) | 治療用抗ｉｇｆ１ｒ合剤 | |
| KR20170065466A (ko) | 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체 | |
| IL323835A (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| JP2025509730A5 (https=) | ||
| US9346846B1 (en) | Anti-cancer compounds and methods for treating cancer | |
| TWI913270B (zh) | 用於癌症治療之結合分子 | |
| JP2025509736A5 (https=) |